Literature DB >> 15231584

Homozygosity for CCTG mutation in myotonic dystrophy type 2.

Benedikt G H Schoser1, Wolfram Kress, Maggie C Walter, Birgit Halliger-Keller, Hanns Lochmüller, Kenneth Ricker.   

Abstract

Myotonic dystrophy type 2 (DM2) is caused by a dominantly transmitted CCTG repeat expansion in intron 1 of the zinc finger protein 9 (ZNF9) gene on chromosome 3q. DM2 patients with two mutant alleles have not been reported so far. In one large consanguineous family from Afghanistan, we found three homozygotes for the DM2 mutation. The oldest patient was clinically more severely affected, compared with the two younger homozygotes, but for the clinical course of symptoms all three homozygotes were within the range expected for heterozygotes. Further investigations, such as mutation repeat length, muscle histology, anti-muscleblind-like 1 stainings or brain imaging studies, at least at short-term observation, showed no differences between heterozygotes and homozygotes. Twenty of 24 children, aged 2-21 years, were available for clinical examination. None of these children have signs or symptoms of disease until the age of 18 years. Homozygosity for the DM2 expansion does not seem to alter the disease phenotype as compared with the heterozygous state.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15231584     DOI: 10.1093/brain/awh210

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  21 in total

1.  Co-segregation of DM2 with a recessive CLCN1 mutation in juvenile onset of myotonic dystrophy type 2.

Authors:  Rosanna Cardani; Marzia Giagnacovo; Annalisa Botta; Fabrizio Rinaldi; Alessandra Morgante; Bjarne Udd; Olayinka Raheem; Sini Penttilä; Tiina Suominen; Laura V Renna; Valeria Sansone; Enrico Bugiardini; Giuseppe Novelli; Giovanni Meola
Journal:  J Neurol       Date:  2012-03-10       Impact factor: 4.849

2.  Why a positive genetic test for myotonic dystrophy type I does not always imply the right diagnosis.

Authors:  S G Meuth; C Kleinschnitz; M Frank; C Wessig; M Bendszus; W Kress; H Wiendl
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12       Impact factor: 10.154

Review 3.  The muscular dystrophies: from genes to therapies.

Authors:  Richard M Lovering; Neil C Porter; Robert J Bloch
Journal:  Phys Ther       Date:  2005-12

Review 4.  Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects.

Authors:  Giovanni Meola; Rosanna Cardani
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

Review 5.  Myotonic dystrophy: disease repeat range, penetrance, age of onset, and relationship between repeat size and phenotypes.

Authors:  Kevin Yum; Eric T Wang; Auinash Kalsotra
Journal:  Curr Opin Genet Dev       Date:  2017-02-14       Impact factor: 5.578

6.  Correlates of tumor development in patients with myotonic dystrophy.

Authors:  Maya Das; Richard T Moxley; James E Hilbert; William B Martens; Lisa Letren; Mark H Greene; Shahinaz M Gadalla
Journal:  J Neurol       Date:  2012-05-23       Impact factor: 4.849

Review 7.  Biomolecular diagnosis of myotonic dystrophy type 2: a challenging approach.

Authors:  Giovanni Meola; Fiammetta Biasini; Rea Valaperta; Elena Costa; Rosanna Cardani
Journal:  J Neurol       Date:  2017-05-26       Impact factor: 4.849

Review 8.  Genetics and molecular pathogenesis of the myotonic dystrophies.

Authors:  John W Day; Laura P W Ranum
Journal:  Curr Neurol Neurosci Rep       Date:  2005-02       Impact factor: 5.081

9.  Reduction of the rate of protein translation in patients with myotonic dystrophy 2.

Authors:  Claudia Huichalaf; Benedikt Schoser; Christiane Schneider-Gold; Bingwen Jin; Partha Sarkar; Lubov Timchenko
Journal:  J Neurosci       Date:  2009-07-15       Impact factor: 6.167

10.  Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms.

Authors:  Benedikt Schoser; Lubov Timchenko
Journal:  Curr Genomics       Date:  2010-04       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.